<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title> &#187; Government Policy</title>
	<atom:link href="http://pharmaexecnews.com/category/government-policy/feed/" rel="self" type="application/rss+xml" />
	<link>http://pharmaexecnews.com</link>
	<description></description>
	<lastBuildDate>Fri, 29 Apr 2011 14:00:12 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Antibiotics – A Possible Cure for Anthrax?</title>
		<link>http://pharmaexecnews.com/biotechnology/antibiotics-cure-anthrax/</link>
		<comments>http://pharmaexecnews.com/biotechnology/antibiotics-cure-anthrax/#comments</comments>
		<pubDate>Wed, 27 Apr 2011 14:00:52 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Healthcare]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11522</guid>
		<description><![CDATA[Anthrax is an acute disease caused by the bacterium Bacillus anthracis. Most forms of the disease are lethal, and it affects both humans and other animals. There are effective vaccines against anthrax, and some forms of the disease respond well to antibiotic treatment.

In the absence of early antibiotic treatment, the respiratory form of anthrax can [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/antibiotics-cure-anthrax/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Generic Fees Gain Traction with FDA Backing</title>
		<link>http://pharmaexecnews.com/biotechnology/generic-fees-gain-traction-fda-backing/</link>
		<comments>http://pharmaexecnews.com/biotechnology/generic-fees-gain-traction-fda-backing/#comments</comments>
		<pubDate>Fri, 04 Mar 2011 14:00:10 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Generics]]></category>
		<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11246</guid>
		<description><![CDATA[It looks as if user fees really are in the offing for generic drugs. After generics makers said last week that they&#8217;re supporting the idea as a way to speed approvals of their products, FDA Commissioner Margaret Hamburg backed it, too. Revamping the current approvals process is &#8220;critical,&#8221; she said, because agency funding won&#8217;t provide [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/generic-fees-gain-traction-fda-backing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Obama&#8217;s Budget Delays Deep Cuts to Physician Payments</title>
		<link>http://pharmaexecnews.com/medical/healthcare-medical/obamas-budget-delays-deep-cuts-physician-payments/</link>
		<comments>http://pharmaexecnews.com/medical/healthcare-medical/obamas-budget-delays-deep-cuts-physician-payments/#comments</comments>
		<pubDate>Wed, 16 Feb 2011 08:00:14 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11168</guid>
		<description><![CDATA[Although President Obama&#8217;s proposed $3.73 trillion budget for 2012 calls for more than $1 trillion in slashed spending, it protects doctors from steep cuts in their Medicare payments with a two year reprieve. The budget delays a scheduled 25 percent cut in the Sustainable Growth Rate, Medicare&#8217;s physician payment formula that was slated to go [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/medical/healthcare-medical/obamas-budget-delays-deep-cuts-physician-payments/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Obama Will Not Refight Battle Over Healthcare Law</title>
		<link>http://pharmaexecnews.com/pharmaceuticals/markets/obama-refight-battle-healthcare-law/</link>
		<comments>http://pharmaexecnews.com/pharmaceuticals/markets/obama-refight-battle-healthcare-law/#comments</comments>
		<pubDate>Thu, 03 Feb 2011 08:00:14 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11131</guid>
		<description><![CDATA[President Barack Obama said on Friday his healthcare overhaul is an important part of efforts to cut the budget deficit and insisted he will not &#8220;refight&#8221; the battle to pass the law. With emboldened Republicans vowing to repeal or replace the healthcare law he signed last March, Obama reiterated his case that the changes it [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/pharmaceuticals/markets/obama-refight-battle-healthcare-law/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Doctor-Patient Relationship Compromised by Facebook</title>
		<link>http://pharmaexecnews.com/biotechnology/doctorpatient-relationship-compromised-facebook/</link>
		<comments>http://pharmaexecnews.com/biotechnology/doctorpatient-relationship-compromised-facebook/#comments</comments>
		<pubDate>Tue, 21 Dec 2010 08:00:02 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10991</guid>
		<description><![CDATA[Researchers surveyed the Facebook activities of 405 postgraduate trainee doctors at Rouen University Hospital in France and found that almost three out of four had a Facebook profile. One in four logged on to the site several times a day, and half logged on several times a week.

Almost half believed that the doctor-patient relationship would [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/doctorpatient-relationship-compromised-facebook/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Docs Must Police Each Other in Social Media</title>
		<link>http://pharmaexecnews.com/biotechnology/docs-police-social-media/</link>
		<comments>http://pharmaexecnews.com/biotechnology/docs-police-social-media/#comments</comments>
		<pubDate>Tue, 07 Dec 2010 08:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10949</guid>
		<description><![CDATA[The American Medical Association wants doctors to blow the whistle on their peers who behave badly online. The new policy is likely a response to concerns about patient confidentiality in social media exchanges, writes Colin Zick in the Foley Hoag law blog.  &#8221;When physicians see content posted by colleagues that appears unprofessional they have a [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/docs-police-social-media/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Amgen Proposes Key Hurdles for Biosimilar Regs</title>
		<link>http://pharmaexecnews.com/biotechnology/amgen-proposes-key-hurdles-biosimilar-regs/</link>
		<comments>http://pharmaexecnews.com/biotechnology/amgen-proposes-key-hurdles-biosimilar-regs/#comments</comments>
		<pubDate>Thu, 11 Nov 2010 08:00:18 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Research Reports]]></category>
		<category><![CDATA[bioengineering]]></category>
		<category><![CDATA[Bioinformatics Market Potential]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10876</guid>
		<description><![CDATA[The FDA&#8217;s marathon run toward a new set of regulations to govern the development of biosimilars is official. Regulators will host their first public meeting on follow-on drug regs, and you can expect to hear plenty from big companies like Amgen on the need for lengthy and expensive clinical trials.

As Reuters notes, the agency has [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/amgen-proposes-key-hurdles-biosimilar-regs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Obama Steps Up Defense of Health-Care Overhaul Law</title>
		<link>http://pharmaexecnews.com/pharmaceuticals/markets/obama-steps-defense-healthcare-overhaul-law/</link>
		<comments>http://pharmaexecnews.com/pharmaceuticals/markets/obama-steps-defense-healthcare-overhaul-law/#comments</comments>
		<pubDate>Mon, 27 Sep 2010 08:00:26 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Research Reports]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding Genomics and Global Health Impacts]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10738</guid>
		<description><![CDATA[President Barack Obama said politicians who want to repeal this year’s health-care overhaul should have to explain to people who need insurance that they won’t be able to buy it. “I want them to look you in the eye and say sorry,” he said, “you can’t buy health insurance.”  “I don’t think that’s what this [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/pharmaceuticals/markets/obama-steps-defense-healthcare-overhaul-law/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Research Scientists Brace for Layoffs as Stimulus Cash Dries Up</title>
		<link>http://pharmaexecnews.com/biotechnology/research-scientists-brace-layoffs-stimulus-cash-dries/</link>
		<comments>http://pharmaexecnews.com/biotechnology/research-scientists-brace-layoffs-stimulus-cash-dries/#comments</comments>
		<pubDate>Fri, 10 Sep 2010 08:00:34 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical Research]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Research Reports]]></category>
		<category><![CDATA[bioengineering]]></category>
		<category><![CDATA[Bioinformatics Market Potential]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10691</guid>
		<description><![CDATA[The stimulus bill that pumped more than $8 billion into biomedical research projects in the U.S. is set to end at the end of the month. And the surge of research work that it helped spawn is likely to come to a quick stop, triggering stinging job losses as research scientists jockey for a piece [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/research-scientists-brace-layoffs-stimulus-cash-dries/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Nanotox&#8217; Research also has Implications for Nano Drug Delivery</title>
		<link>http://pharmaexecnews.com/biotechnology/nanotox-research-implications-nano-drug-delivery/</link>
		<comments>http://pharmaexecnews.com/biotechnology/nanotox-research-implications-nano-drug-delivery/#comments</comments>
		<pubDate>Wed, 01 Sep 2010 08:00:34 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Nanotechnology]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Research Reports]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[bioengineering]]></category>
		<category><![CDATA[Bioinformatics Market Potential]]></category>
		<category><![CDATA[biomolecules]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[micro technology]]></category>
		<category><![CDATA[molecular biology]]></category>
		<category><![CDATA[nano]]></category>
		<category><![CDATA[nanobiotechnology]]></category>
		<category><![CDATA[nanotechnology]]></category>
		<category><![CDATA[Nanotechnology - Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10665</guid>
		<description><![CDATA[A relatively recent subgroup of nanotech research is what is beginning to be commonly referred to as &#8220;nanotox,&#8221; or the study of how nanoparticles react to the environment and human body. It is a line of inquiry that directly arose out of concerns that if engineered nanoscale particles have the potential to do great things [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/nanotox-research-implications-nano-drug-delivery/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

